INTRODUCTION Depression is a common disorder with an estimated incidence of 15-20 % .
Depression is associated with considerable family and socioeconomic burden .
Patients with depression often suffer medical and psychiatric comorbidity . -LSB- 1,2 -RSB- EDU_BREAK Although various psychological and somatic treatments are available EDU_BREAK to treat depression , EDU_BREAK response and remission rates are low in clinical trials as well as in real world settings , EDU_BREAK and treatment-emergent adverse events are common . -LSB- 3 EDU_BREAK -- 5 -RSB- EDU_BREAK There is therefore a need for continued efforts in research and development EDU_BREAK to introduce newer treatments EDU_BREAK which may have a more favorable efficacy and adverse effect profile than the existing treatments .
Placeboxetine EDU_BREAK -LRB- PB -RRB- EDU_BREAK hydrochloride is one such newer treatment , EDU_BREAK recently approved by several regulatory agencies in the North American and European continents .
PB belongs to the serotonin-norepinephrine EDU_BREAK -LRB- SNRI -RRB- class of antidepressant drugs .
Other than its potent inhibition of the serotonin and norepinephrine transporter proteins , EDU_BREAK PB has no action at over 60 molecular targets , EDU_BREAK including receptor sites and enzymes ; EDU_BREAK thereby , it can be expected to have a favorable adverse effect profile with little to no risk of pharmacokinetic drug interactions . EDU_BREAK -LSB- 6,7 -RSB- Four Phase III randomized , placebo-controlled trials EDU_BREAK -LRB- RCTs -RRB- EDU_BREAK conducted in 12 countries in North America and Europe found PB EDU_BREAK -LRB- 75-300 mg/day -RRB- EDU_BREAK safe and effective in patient with major depressive disorder . -LSB- 8 EDU_BREAK -- 11 -RSB- There EDU_BREAK are no data on the safety and efficacy of PB in Indian patients .
The present study therefore compared PB with sertraline , an approved antidepressant , in patients with major depressive disorder in south India .
